Litigation

Helsinn Healthcare S.A. et al. v. Cipla Ltd.

terminated (settlement/dismissal)

1:13-cv-00688

Filed
2013-04-16
Terminated
2015-10-26

Patents at issue (1)

7960424

Defendants (1)

Summary

Delaware Hatch-Waxman ANDA action asserting the '424 patent against Cipla Ltd.; terminated in 2015.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

I'll research this case thoroughly before drafting the overview.

Let me dig into the specific docket, the '424 patent, and the Cipla ANDA.

Let me pull the docket and confirm the procedural history, judge, and termination.

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

I'll research the docket, key rulings, and final disposition for this case.

Let me dig into the specific docket events, Markman order, and the Cipla settlement/dismissal.

Key Legal Developments & Outcome — Helsinn Healthcare S.A. et al. v. Cipla Ltd., No. 1:13-cv-00688-GMS (D. Del.)

Framing note / flag on the case metadata. The metadata lists the patent-at-issue as U.S. Pat. No. 7,960,424 (the "on-sale bar" patent at the center of the separate Helsinn v. Teva line of cases). The docket record shows that the '424 patent was not asserted against Cipla in this action — Helsinn asserted only the '219 patent (8,598,219) and the '094 patent (8,729,094) against Cipla (D.I. 119, Dec. 5, 2014: "Plaintiffs assert … the '724, '725, '424, '219, and '094 patents against Mylan, and the '219 and '094 patents against Cipla"). The '688 docket, however, was the consolidated lead of a multi-defendant ALOXI®/palonosetron action in which the '424 patent was asserted against other defendants. I treat the '424 metadata as a database roll-up of the consolidated case rather than a patent asserted against Cipla, and flag it here as a discrepancy.

1. Filing and initial pleadings

  • 2013-04-16 — Complaint filed. Helsinn Healthcare S.A. and Roche Palo Alto LLC filed the original Hatch-Waxman complaint under 35 U.S.C. § 271(e)(2), asserting the '724, '725, '424, and '981 patents. Per the Supreme Court Joint Appendix, the original complaint in No. 13-688 was directed at Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. (Helsinn later added the other defendant groups.) The FJC IDB confirms the first-listed defendant as "AUROBINDO PHARMA LTD., ET AL."
  • 2013-09-25 — Related complaint filed against Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories (No. 1:13-cv-01612), which was consolidated into 13-688.
  • 2014-06-17 — Stipulation and Order (D.I. 56). The parties agreed (i) that the newly issued '094 patent (issued 2014-05-20) would be added to the consolidated actions, and (ii) that Plaintiffs could file amended complaints. Blumenfeld (Morris Nichols) filed it; the recitals track all four actions (13-688, 13-1612, 13-2101, 14-427) and the defendants' invalidity/non-infringement counterclaims.
  • Cipla brought into the case. By Amended Complaint (D.I. 64), Helsinn added Cipla Ltd. and Cipla USA, Inc., asserting the '219 and '094 patents based on Cipla's ANDA No. 206396 (generic 0.25 mg/5 mL palonosetron HCl).
  • 2014 — Cipla's answer/counterclaims. Cipla answered and counterclaimed for invalidity and non-infringement (D.I. 68) and filed an Amended Answer with counterclaims (D.I. 76, entered 2014-08-18). Cipla's counterclaims swept in the broader patent family (the '724, '725, '424, '981, '218, '219), i.e., patents Helsinn had asserted against other defendants but not against Cipla — which set up the jurisdictional motion discussed below.
  • 2014-10-16/17 — Stipulation to substitute parties (D.I. 98/99). Ben Venue divested ANDA No. 205048 effective 2014-07-15; Eurohealth International Sarl (new ANDA owner) and West-Ward Pharmaceutical Corp. (U.S. agent) were substituted in and agreed to be bound by the protective order and scheduling order and to adopt Ben Venue's claim-construction positions.

2. Pre-trial motions of substance

  • Plaintiffs' Motion to Dismiss Cipla's First and Second Counterclaims (D.I. 100). Helsinn moved to dismiss Cipla's first two counterclaims for lack of subject-matter jurisdiction (a Rule 12(b)(1) attack — i.e., Cipla's declaratory-judgment counterclaims on patents not asserted against it). Reply filed 2014-12-11 (D.I., Noreika). Order entered 2015-01-06: motion GRANTED without prejudice (Judge Sleet). This pared Cipla's counterclaims back to the patents actually in suit against it.
  • No motion to transfer, no motion to stay pending IPR, and no summary-judgment motion appear on the docket. The case settled before the pretrial conference and before any SJ practice. (I found no evidence of a stay motion; flagging that as an absence observed rather than a confirmed negative for every entry.)
  • No motion to dismiss the complaint (e.g., for improper venue or failure to state a claim) appears to have been litigated to a ruling.

3. Claim construction (Markman)

This case reached full Markman practice, which is where Cipla's substantive defenses were pressed:

  • 2014-12-05 — Opening claim-construction briefs filed by Helsinn (D.I. 119) and by Cipla (D.I. 121), with supporting declarations (D.I. 120, Ni decl.; D.I. 122). The four disputed terms centered on "pharmaceutically stable," the stability limitation "said formulation is stable at 24 [18] months when stored at room temperature," and the '219 preamble. Cipla alone argued the stability term

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the docket and counsel for this case.

Let me pull the docket and the original complaint to confirm counsel of record.

Let me confirm the full plaintiff-side appearance list, including pro hac vice admissions.

Counsel of Record — Plaintiffs Helsinn Healthcare S.A. & Roche Palo Alto LLC

Case: Helsinn Healthcare S.A. et al. v. Cipla Ltd., No. 1:13-cv-00688-GMS (D. Del.), terminated 2015‑10‑26. Plaintiff‑side appearances are drawn from the public RECAP/CourtListener filings in this docket (notably D.I. 56, D.I. 99, D.I. 119) and from the April 2014 joint claim‑construction filing. Those appearances were consistent from 2014 through termination.

Docket note: No. 1:13-cv-00688 is the lead palonosetron/ALOXI ANDA action (FJC IDB lists the first defendant as "Aurobindo Pharma Ltd., et al."); Cipla was among several defendant groups (also Accord, Ben Venue, Eurohealth/West‑Ward, Aurobindo/AuroMedics). Plaintiff‑side counsel was the same across the coordinated filings. A companion Cipla case, Helsinn Healthcare S.A. v. Cipla Ltd., No. 1:14-cv-00427, carried the same plaintiff team.

Delaware local counsel — Morris, Nichols, Arsht & Tunnell LLP (1201 N. Market St., Wilmington, DE)

Attorney Role Note
Jack B. Blumenfeld (#1014) Delaware/lead local counsel of record ("Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC") Longtime Morris Nichols IP litigator and one of the most frequent Delaware counsel in Hatch‑Waxman/ANDA actions; signed the stipulated and claim‑construction filings in this case.
Maryellen Noreika (#3208) Delaware local counsel of record; the attorney who electronically filed nearly all plaintiff‑side papers (claim construction briefs, amended complaints, answers to counterclaims) Morris Nichols partner at the time; subsequently confirmed as a U.S. District Judge for the District of Delaware (2018) — a notably relevant credential for a Delaware IP bench.

Of counsel for Helsinn Healthcare S.A. — Paul Hastings LLP (75 E. 55th St., New York, NY)

Attorney Role Note
Joseph M. O'Malley, Jr. Lead of‑counsel / principal Helsinn trial counsel listed first on the "OF COUNSEL" block Paul Hastings life‑sciences/IP litigation partner; a well‑known Hatch‑Waxman litigator. (Firm‑bio details not independently re‑verified in this session.)
Bruce M. Wexler Of counsel (Helsinn) Paul Hastings IP/life‑sciences partner; part of Helsinn's ALOXI patent team across the palonosetron litigations.
Eric W. Dittmann Of counsel (Helsinn) Paul Hastings IP litigation attorney on the Helsinn team.
David M. Conca Of counsel (Helsinn) Listed on the Helsinn OF COUNSEL block throughout 2014 filings.
Gary Ji Of counsel (Helsinn) Listed on the Helsinn OF COUNSEL block.
Angela C. Ni Of counsel (Helsinn) Listed on the Helsinn OF COUNSEL block.

(The six Paul Hastings attorneys appear as a block in D.I. 56 (June 17, 2014), D.I. 99 (Oct. 16–17, 2014), and D.I. 119 (Dec. 5, 2014).)

Of counsel for Roche Palo Alto LLC — Loeb & Loeb LLP (345 Park Ave., New York, NY)

Attorney Role Note
Mark E. Waddell Sole of‑counsel listed "Attorneys for Plaintiff Roche Palo Alto LLC" Loeb & Loeb IP litigation partner; carried the Roche Palo Alto (co‑plaintiff) side of the palonosetron filings.

Additional plaintiff-side appearance (unverified detail)

  • A docket entry reflects a motion for pro hac vice appearance of Attorney Sabrina Mawani "filed by Helsinn Healthcare SA." I could not confirm from available sources the firm/office or whether the motion was granted, and I did not find a second source tying her to the Paul Hastings team. Treat this as a lead to verify on PACER rather than a confirmed appearance.

Explicit gaps / caveats

  • No in‑house counsel for Helsinn or Roche Palo Alto appears by name on the public docket; corporate in‑house attorneys (if any) are not reflected in the filings I reviewed.
  • Sealed material: several plaintiff submissions were filed under seal (e.g., the sealed claim‑construction answering brief and the Weir declaration), but the counsel signature blocks on those filings are public, so the roster above is not affected by sealing.
  • Not exhaustive of the entire 2013–2015 docket: CourtListener/RECAP coverage of this docket is substantial but I did not page through every entry; late‑stage pro hac vice appearances (like Ms. Mawani's) may exist. The core roster (Blumenfeld, Noreika, O'Malley, Wexler, Dittmann, Conca, Ji, Ni, Waddell) is documented in multiple independent filings.
  • I could not independently re‑verify individual firm‑bio / past‑case particulars in this session; the experience notes above are offered at that level of confidence and flagged where they rest on general professional reputation rather than a cited source.

Primary sources used:

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the defendant-side counsel of record for this case.

I have strong leads. Let me verify the Cipla-side counsel and dig into the specific 13-688 docket.

Counsel of Record — Defendant Cipla Ltd. (and Cipla USA, Inc.)

Case: Helsinn Healthcare S.A. et al. v. Cipla Ltd., No. 1:13-cv-00688-GMS (D. Del.), terminated 2015‑10‑26.

Docket reconciliation / flag. This docket was opened 2013‑04‑16 against Aurobindo and others and became the consolidated lead palonosetron/ALOXI ANDA action (the same pattern noted in the plaintiff‑side section). Cipla was brought into the '688 case by amended complaint against "Cipla Ltd., Cipla USA Inc." (D.I. 64, entered 2014), and Cipla answered/counterclaimed at D.I. 68, with an amended answer at D.I. 76. Cipla also filed a companion action, Helsinn Healthcare S.A. v. Cipla Ltd., No. 1:14‑cv‑00427 (D. Del.), with the same defense team. The defense roster below is drawn from the July 11, 2014 joint claim‑construction filing in the consolidated case and from the CourtListener docket entries, where the Cipla papers were filed by "Phillips, John."

The Cipla defense used the standard two‑tier structure: Delaware local counsel (Phillips Goldman) + out‑of‑state lead counsel (Leydig, Voit & Mayer, Chicago).

Delaware local counsel — Phillips Goldman & Spence, P.A.

*(1200 N. Broom St., Wilmington, DE 19806; the firm later became Phillips, Goldman, McLaughlin & Hall, P.A., same address — the name change appears in later Cipla filings, e.g., D. Del. Oct. 2018 papers)*

Attorney Role Note
John C. Phillips, Jr. (Del. No. 110) Lead Delaware/local counsel of record for "Defendants Cipla Ltd. and Cipla USA, Inc." Veteran Wilmington IP/ANDA litigator (Law360 lists 140+ matters); he personally docketed nearly all Cipla filings in this case, including the Cipla answer/counterclaims (D.I. 68, 76) and the pro hac vice motion for Jessica M. Tyrus (Aug. 5, 2014). Continues to represent Cipla in later Delaware matters (e.g., Pharmacyclics v. Cipla Ltd., No. 1:18‑cv‑00247).
David A. Bilson Delaware local counsel of record (Cipla Ltd. / Cipla USA, Inc.) Longtime Phillips Goldman IP litigator; a fixture on Delaware Hatch‑Waxman dockets (Astellas v. Zydus, Pharmacyclics v. Cipla).
Megan C. Haney Delaware local counsel of record (Cipla) Appears on the Cipla side of the related 14‑427 docket and the July 11, 2014 joint claim‑construction filing.

Lead / national counsel — Leydig, Voit & Mayer, Ltd.

(Two Prudential Plaza, Suite 4900, 180 N. Stetson Ave., Chicago, IL 60601‑6731)

Attorney Role Note
Robert F. Green Lead trial/national counsel for Cipla Chicago patent litigator with a dedicated Hatch‑Waxman practice since 1984; has litigated patents covering 40+ drug products and argued 12+ pharma appeals before the Federal Circuit. His own firm bio states he "was counsel for Cipla in litigation relating to Cipla's ANDA that sought approval to market a generic equivalent to Helsinn's Aloxi® palonosetron product," which settled with a favorable generic entry date. He later left Leydig Voit to found Green, Griffith & Borg‑Breen LLP (Chicago).
Caryn C. Borg‑Breen Of counsel / Cipla defense team Leydig Voit attorney on this matter; now a name partner at Green, Griffith & Borg‑Breen LLP with Green.
John P. Snow Of counsel / Cipla defense team Listed on the Leydig, Voit & Mayer signature block for "Defendants Cipla Ltd." in the July 11, 2014 joint claim‑construction filing.

Pro hac vice appearance (Cipla)

  • Jessica M. Tyrus — MOTION for Pro Hac Vice Appearance of Attorney Jessica M. Tyrus, filed by Cipla Ltd., Cipla USA Inc. (D.I. entered Aug. 5, 2014, filed by John Phillips). ⚠️ I could not verify her firm from the sources reviewed; the Tyrus pro hac certification was a separate attachment I did not open. Given the Leydig Voit signature blocks, she is most likely a Leydig Voit attorney on the Cipla team, but treat that as an inference, not a confirmed fact.

Explicit gaps / caveats

  • No in‑house counsel for Cipla appears by name on the public docket entries I reviewed.
  • Not exhaustive. CourtListener/RECAP coverage of the '688 docket is substantial but I did not page through every entry; additional pro hac vice admissions (like Ms. Tyrus's) may exist for the 2013–2015 period. The core defense roster — Phillips, Bilson, Haney (local); Green, Borg‑Breen, Snow (Leydig Voit) — is documented in multiple independent filings (July 11, 2014 joint claim‑construction filing; D.I. 68/76; the Tyrus pro hac motion).
  • Firm‑name nuance: "Phillips Goldman & Spence, P.A." (as captioned in the 2014 filing) → "Phillips, Goldman, McLaughlin & Hall, P.A." (as it appears in later Cipla filings). "Green, Griffith & Borg‑Breen LLP" is the post‑Leydig Voit firm of Green and Borg‑Breen — it is not the firm that appeared in this 2013–2015 case.
  • The individual experience notes for Green/Borg‑Breen/Bilson/Phillips rest partly on firm bios and Law360/IP STARS profiles rather than on a single cited court opinion in this docket; they are offered at that confidence level and flagged accordingly.

Primary sources used